Synthorx Throws THOR-707 Into Competitive IL-2 Space With HAMMER, Its First-Ever Clinical Trial
Emerging Company Profile: This is the first human study for lead product candidate THOR-707 and for the company's Expanded Genetic Alphabet platform, starting with a recombinant IL-2 that's being tested in solid tumors.
You may also be interested in...
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.